PCN83 A COST-EFFECTIVENESS ANALYSIS (CEA) FOR DENOSUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY FOR CANCER TREATMENTINDUCED BONE LOSS (CTIBL) IN NON-METASTATIC PROSTATE CANCER (PRCA)- A SWEDISH PERSPECTIVE
Nov 1, 2010, 00:00
10.1016/S1098-3015(11)71978-7
https://www.valueinhealthjournal.com/article/S1098-3015(11)71978-7/fulltext
Title :
PCN83 A COST-EFFECTIVENESS ANALYSIS (CEA) FOR DENOSUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY FOR CANCER TREATMENTINDUCED BONE LOSS (CTIBL) IN NON-METASTATIC PROSTATE CANCER (PRCA)- A SWEDISH PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)71978-7&doi=10.1016/S1098-3015(11)71978-7
First page :
A266
Section Title :
RESEARCH POSTER ABSTRACTS
Open access? :
No
Section Order :
134